Davita Inc (NYSE:DVA) has been given an average recommendation of “Hold” by the twelve brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $64.57.
A number of equities research analysts have issued reports on DVA shares. Royal Bank of Canada reissued a “hold” rating and set a $65.00 price target on shares of Davita in a research report on Wednesday, January 9th. SunTrust Banks reissued a “hold” rating on shares of Davita in a research report on Wednesday, February 20th. Deutsche Bank initiated coverage on Davita in a research report on Thursday, January 3rd. They set a “buy” rating and a $60.00 price target for the company. Barclays initiated coverage on Davita in a research report on Friday, December 14th. They issued an “overweight” rating and a $70.00 target price for the company. Finally, Robert W. Baird decreased their target price on Davita from $90.00 to $70.00 and set an “outperform” rating for the company in a research report on Friday, February 15th. They noted that the move was a valuation call.
Hedge funds and other institutional investors have recently modified their holdings of the company. Oakbrook Investments LLC boosted its position in shares of Davita by 60.5% in the fourth quarter. Oakbrook Investments LLC now owns 12,950 shares of the company’s stock worth $666,000 after buying an additional 4,880 shares during the period. Zeke Capital Advisors LLC acquired a new position in shares of Davita in the third quarter worth about $359,000. Contravisory Investment Management Inc. lifted its stake in shares of Davita by 8.2% in the fourth quarter. Contravisory Investment Management Inc. now owns 3,932 shares of the company’s stock worth $202,000 after acquiring an additional 298 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its stake in shares of Davita by 61.1% in the fourth quarter. Oppenheimer Asset Management Inc. now owns 77,571 shares of the company’s stock worth $3,992,000 after acquiring an additional 29,410 shares in the last quarter. Finally, Mackenzie Financial Corp lifted its stake in shares of Davita by 3.6% in the fourth quarter. Mackenzie Financial Corp now owns 1,321,520 shares of the company’s stock worth $68,005,000 after acquiring an additional 46,408 shares in the last quarter. 85.66% of the stock is owned by institutional investors.
DVA stock traded down $0.05 during trading on Friday, reaching $53.53. 2,110,871 shares of the stock traded hands, compared to its average volume of 1,763,127. Davita has a 52-week low of $48.25 and a 52-week high of $79.11. The company has a current ratio of 1.72, a quick ratio of 1.70 and a debt-to-equity ratio of 2.09. The company has a market cap of $8.96 billion, a PE ratio of 14.99, a price-to-earnings-growth ratio of 0.51 and a beta of 1.30.
Davita (NYSE:DVA) last posted its quarterly earnings results on Wednesday, February 13th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.89 by $0.01. Davita had a return on equity of 14.17% and a net margin of 1.40%. The firm had revenue of $2.82 billion during the quarter, compared to the consensus estimate of $2.97 billion. During the same quarter in the previous year, the business earned $0.92 earnings per share. The firm’s quarterly revenue was up 1.4% compared to the same quarter last year. Equities analysts forecast that Davita will post 4.43 EPS for the current fiscal year.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Article: Can systematic risk be avoided?
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.